The Food and Drug Administration (FDA) announced that the laboratory analysis found inconsistent amounts of belladonna in some homeopathic teething tablets, with levels higher than what is claimed on the label.
Few pediatric patients having a dental procedure combined with another surgical procedure require unplanned admission for perioperative concerns.
After the FDA's safety alert regarding homeopathic teething tablets in 2010, the Agency has been evaluating reported adverse events related to use of these products such as seizures.
St. Renatus announced that the Food and Drug Administration (FDA) has approved Kovanaze (tetracaine HCl and oxymetazoline HCl) Nasal Spray, the first dental anesthetic administered as a nasal spray.
The FDA has issued a warning that prescription oral viscous lidocaine 2% solution should not be used to treat infants and children with teething pain, and that OTC topical medications may also be harmful and should not be used.
The FDA announced that it will allow manufacturers of OTC oral health care products containing benzocaine to include a product label warning regarding the risks of methemoglobinemia associated with these products.
For patients with planned dental extraction before cardiac surgery, the risk of a major adverse outcome is 8%, including a 3% risk of death before surgery.
The American College of Obstetricians and Gynecologists (ACOG) recommends that physicians discuss oral health with all patients, including those who are pregnant or postpartum.
The FDA notified healthcare professionals and patients that it has continued to receive reports of methemoglobinemia associated with benzocaine products.